Feature Video
Sponsored Content: Dr. Shannon Westin on PARP Inhibition for Ovarian Cancer
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
USPSTF Says Ovarian Cancer Screening Is Unnecessary for Most Women
BY Brielle Urciuoli
Ovarian cancer screening for women who do not have symptoms of the disease may do more harm than good, according to the USPSTF.
Combinations May Be the Future for Ovarian Cancer
BY Wayne Kuznar
Immunotherapy and PARP inhibitor combinations may be the future of ovarian cancer treatment, says Samir N. Khleif, M.D.
Don't Let Ovarian Cancer Take Away Your Sex Life
BY Katie Kosko
Many patients with cancer don't hesitate when discussing side effects like fatigue, nausea and neuropathy with their health care provider; however, there is often silence when it boils down to the sexual side effects of their treatment.
PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment
BY Lauren M. Green
The treatment landscape of ovarian cancer continues to change with the recent approvals of new agents.
Audra Moran on the Ovarian Cancer National Conference
BY Audra Moran
Audra Moran, CEO & President of the Ovarian Cancer Research Fund Alliance discusses the Ovarian Cancer National Conference.
David Gershenson on Challenges to Advancing Treatment for Rare Ovarian Cancers
BY David Gershenson, M.D.
David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors.
Maintenance Rubraca Has Potential in Ovarian Cancer
BY Jason Harris
For women with platinum-sensitive, high-grade ovarian, fallopian tube or primary peritoneal cancer, an improved progression-free survival (PFS) was seen for those who took Rubraca (rucaparib) as a maintenance therapy, compared to placebo, according to the phase 3 ARIEL3 trial.
Clinical Trials Are the Way Forward for Ovarian Cancer, but They Need Advocates at Every Level
BY Lauren M. Green
For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.
Fruits, Vegetables and Water are Key Components of a Healthy Diet During and After Ovarian Cancer
BY Beth Fand Incollingo
Strategies from expert oncology dieticians can help patients to eat an appropriate diet and maintain a healthy weight during and after treatment for ovarian cancer.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
BY Sarah Sciortino, MSW, LSW
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Ovarian Epithelial Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial cancer.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment.
Ovarian Germ Cell Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian germ cell tumors.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Ovarian Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing ovarian cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Ovarian Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for ovarian cancer.